Advanced therapies for the treatment of hemophilia: future perspectives

Table 2 Some molecular and physiological characteristics of hemophilia A and B

Type of hemophilia	Deficient factor	Protein size (Kilodaltons)	DNA length (bp)	Half life (Hours)	Function in the coagulation cascade	Plasma concentration (ng/ml)^1,2
						Mild hemophilia	Moderately Severe Hemophilia	Severe Hemophilia
Hemophilia A	VIII	280	7056	8-12	Activated by thrombin and activates to FX³	10-80 (5-40%)	2-10 (1-5%)	< 2 (<1%)
Hemophilia B	IX	68	1389	15-25	Activated by FXIa⁴, and activates to FX	500-2000 (5-40%)	50-500 (1-5%)	< 50 (<1%)

¹Normal plasma level of coagulation factors: Factor VIII, 200 ng/mL; factor IX, 5000 ng/mL; ²One International Unit (IU) of factor VIII or IX, per kg of body weight, increases the activity of factor in plasma, 1% to 2% of normal level; ³FX, factor X; ⁴FXIa, factor XI activated.

ISSN: 1750-1172